Latest Developments in Weight-Loss Drugs and Neuralink Trials

The US FDA now lists all doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro as available, though they remain on the shortage list. Meanwhile, Neuralink, owned by Elon Musk, has implanted its brain chip in a second patient, enabling use of digital devices through thought.

The US Food and Drug Administration has reported that all doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are currently available. Despite this update, both medications remain on the FDA's shortage list.

In another significant health development, Neuralink, the neurotechnology company owned by Elon Musk, has successfully implanted its brain chip in a second trial patient. This device aims to empower paralyzed individuals to control digital devices solely through thought.

The first patient implanted with the brain chip demonstrated the capability to play video games, browse the internet, post on social media, and manipulate a cursor on a laptop, suggesting potential for substantial improvements in quality of life for those with spinal cord injuries.

(With inputs from agencies.)